
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences Inc is experiencing a positive shift in its financial outlook, as indicated by an increased probability of success (PoS) for the darovasertib program to 70%, alongside promising preclinical and early clinical results demonstrating anti-tumor responses in metastatic uveal melanoma. The synergy observed between darovasertib and crizotinib highlights a strengthened efficacy profile, suggesting improved safety and tolerability outcomes, which could significantly enhance the company's revenue projections beyond the current estimate of ~$3.2 billion. With ongoing Phase 3 trials and multiple catalysts on the horizon, combined with strong clinical data showing meaningful survival benefits, IDEAYA's portfolio appears well-positioned to capture value in the oncology market despite the niche nature of uveal melanoma.
Bears say
The analysis of IDEAYA Biosciences Inc reveals several fundamental concerns contributing to a negative outlook on its stock. Key risks include the company's non-revenue-generating status, unpredictability of future revenues and expenses, and potential delays or limitations in commercialization due to negative trial outcomes, unexpected safety signals, or adverse regulatory decisions. Furthermore, the potential failure of IDE397 and IDE849 to yield competitive clinical results, along with the concentration risk associated with darovasertib's success in clinical and commercial execution, heightens the uncertainties surrounding IDEAYA's market positioning and investor confidence.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares